TCRR
Income statement / Annual
Last year (2022), TCR2 Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, TCR2 Therapeutics Inc.'s net income was -$151.82 M.
See TCR2 Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$98.64 M
|
$77.24 M
|
$51.98 M
|
$37.49 M
|
$19.67 M
|
$9.57 M
|
$7.67 M
|
| General & Administrative
Expenses |
$24.44 M
|
$22.50 M
|
$16.72 M
|
$13.89 M
|
$6.78 M
|
$3.61 M
|
$2.26 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$24.44 M
|
$22.50 M
|
$16.72 M
|
$13.89 M
|
$6.78 M
|
$3.61 M
|
$2.26 M
|
| Other Expenses |
$30.42 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$123.08 M |
$99.74 M |
$68.70 M |
$51.38 M |
$26.45 M |
$13.18 M |
$9.93 M |
| Cost And Expenses |
$123.08 M |
$99.74 M |
$68.70 M |
$51.38 M |
$26.45 M |
$13.18 M |
$9.93 M |
| Interest Income |
$1.94 M |
$224,000.00 |
$1.74 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$58.90 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$63.88 M
|
$2.83 M
|
$1.59 M
|
$862,000.00
|
$419,000.00
|
$298,000.00
|
$220,000.00
|
| EBITDA |
-$89.62 M
|
-$96.92 M
|
-$67.11 M
|
-$50.52 M
|
-$23.83 M
|
-$12.77 M
|
-$9.70 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$1.94 M
|
$224,000.00
|
$1.74 M
|
$3.89 M
|
$2.20 M
|
$110,000.00
|
$15,000.00
|
| Income Before Tax |
-$151.56 M |
-$99.52 M |
-$66.96 M |
-$47.50 M |
-$24.25 M |
-$13.07 M |
-$9.92 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$261,000.00 |
$289,000.00 |
$161,000.00 |
$102,000.00 |
$2.20 M |
$110,000.00 |
$15,000.00 |
| Net Income |
-$151.82 M |
-$99.81 M |
-$67.12 M |
-$47.60 M |
-$24.25 M |
-$13.07 M |
-$9.92 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-3.93 |
-2.63 |
-2.4 |
-2.26 |
-1.05 |
-2.55 |
-1.93 |
| EPS Diluted |
-3.93 |
-2.63 |
-2.4 |
-2.26 |
-1.05 |
-2.55 |
-1.93 |
| Weighted Average Shares
Out |
$38.63 M
|
$37.94 M
|
$27.99 M
|
$21.10 M
|
$23.19 M
|
$5.13 M
|
$5.13 M
|
| Weighted Average Shares
Out Diluted |
$38.63 M
|
$37.94 M
|
$27.99 M
|
$21.10 M
|
$23.19 M
|
$5.13 M
|
$5.13 M
|
| Link |
|
|
|
|
|
|
|
